# GLIA Diagnostics

> GLIA Diagnostics is developing a fingerstick, microRNA-based point-of-care platform for objective assessment and monitoring of traumatic brain injury.

GLIA Diagnostics (GLIA) is an Australian medtech company developing a fingerstick, microRNA (miRNA)-based point-of-care (PoC) platform intended to support the assessment and monitoring of traumatic brain injury (TBI). The system is designed to combine a disposable biosensor cartridge with a handheld electrochemical reader, targeting results in approximately 20 minutes. The technology is investigational and in development; it is not approved for commercial clinical use.

Key facts:
- Founded 2015, headquartered in Sydney, Australia, with a US entity established to support future US programs.
- Biomarker programme assessed at TRL 7; integrated device and cartridge development remain in progress.
- Three-family IP portfolio: licensed biomarker IP plus two GLIA-owned patent families covering the point-of-care platform and diagnostic/prognostic methods.
- Five clinical studies completed, including four peer-reviewed publications, with further validation research planned or underway.
- Seven proprietary candidate miRNA biomarkers.

Current priorities GLIA is seeking:
- Clinical and biobank partners for validation studies
- Strategic medtech and manufacturing collaborators
- Defence and sports organisations for future field studies
- Investors to support MVP completion and regulatory readiness

Contact: ed@gliadiagnostics.com — https://www.gliadiagnostics.com/